Migraine with Brainstem Aura Market Research Report – Forecast to 2027

Global Migraine with Brainstem Aura Research Report: By Diagnosis (Magnetic Resonance Imaging, Other), by Treatment (Abortive Medication, Other), by Distribution Channel (Retail Pharmacies, Other), End-User (Hospitals & Clinics, Other)– Forecast Till 2027

ID: MRFR/Pharma/4944-HCR | | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


Global migraine with brainstem aura market is expected to grow significantly over the forecast period. A migraine with brainstem aura is also known as a basilar migraine or basilar artery migraine. It is a rare type of a migraine that begins in the base of the brain (brain stem). A migraine with brainstem aura occurs in about 1.5% of the patients suffering from with a headache. This migraine can occur in men and women of all ages.


The symptoms of this migraine include visual disturbances in both eyes, vertigo, hearing problems, nausea, dizziness among others. A migraine with brainstem aura (MBA) may affect one or both the sides of the brain. This rare migraine may be caused by a constriction of blood vessels that limit the blood flow to the brain. Moreover, certain external factors such as stress, motion sickness, epilepsy, alcoholism, prolonged hunger, excessive use of headache medications can trigger basilar artery migraines.


The factors such as rising prevalence of a migraine and growing awareness about rare types of migraines in the developed economies are major drivers for the market growth. In addition, the rising need for better treatment approaches, increasing investment of biotechnology and pharmaceutical industries in research & development (R&D) are expected to contribute to the growth of the market. However, side effects associated with migraine treatment drugs may hamper the growth of the market during the forecast period.


Segmentation


The global migraine with brainstem aura market has been segmented into diagnosis, treatment, distribution channel, and end-user.


The market, by diagnosis, has been segmented into magnetic resonance imaging (MRI), computerized tomography (CT), and others.


The market, on the basis of treatment, has been segmented into abortive medication and preventive medication. The abortive medication segment has been segmented into non-steroidal anti-inflammatory drugs (NSAIDs), anti-nausea medications, and others. The preventive medication segment has been further segmented into botox injections, antidepressants, and others.


On the basis of the distribution channel, the market has been segmented into retail pharmacies, hospital pharmacies, and others.


The market, by end-user, has been segmented into hospital & clinics, diagnostic centers, and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The migraine with brainstem aura market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European migraine with brainstem aura market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The migraine with brainstem aura market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The migraine with brainstem aura market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players


Allergen Plc, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories, AstraZeneca, Eisai Co., Ltd., Endo International Plc, Impax Laboratories, Eli Lily and Company, and Johnson & Johnson are some of the key players in the global migraine with brainstem aura market.


Regional Market Summary


Global Migraine with Brainstem Aura Market Share (%), by Region, 2017


Migraine with Brainstem Aura Market Share


Source: Centers for Disease Control and Prevention (CDC), White Papers, Company Presentations, Annual Reports


Geographically, the Americas is anticipated to dominate the global migraine with brainstem aura market owing to a well-developed healthcare sector, rising prevalence of migraine and growing healthcare expenditure. According to the Centers for Disease Control and Prevention (CDC), in 2015, 20% of women and 9.7% of men aged 18 or more had a migraine. Additionally, the large number of research and development (R&D) activities contributes to the growth of the market.


Europe is expected to hold the second largest position in the global migraine with brainstem aura. The market growth in this region is attributed to the availability of funds for research, growing prevalence of migraine, and increasing healthcare expenditure. According to the World Health Organization (WHO), it is estimated that around 1 in 7 people in the UK experience migraine. It also stated that there are around 190,000 migraine attacks in the UK.


The migraine with brainstem aura market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is anticipated to be the fastest growing region in the market due to continuously developing economies, rising prevalence of migraine and increasing government funding for the healthcare sector.


On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.


Global Migraine with Brainstem Aura Market, by Diagnosis



  • Magnetic Resonance Imaging (MRI)

  • Computerized Tomography (CT)

  • Others


Global Migraine with Brainstem Aura Market, by Treatment



  • Abortive Medication

  • Non-steroidal anti-inflammatory drugs (NSAIDS)

  • Ibuprofen

  • Others

  • Anti-nausea Medications

  • Others



  • Preventive Medication

  • Botox Injections

  • Antidepressants

  • Others


Global Migraine with Brainstem Aura Market, by Distribution Channel



  • Retail Pharmacies

  • Hospital Pharmacies

  • Others


Global Migraine with Brainstem Aura Market, by End-User



  • Hospital & Clinics

  • Diagnostic Centers

  • Others


Global Migraine with Brainstem Aura Market, by Region



  • Americas



  • North America

  • US

  • Canada

  • South America



  • Europe



  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe



  • Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific



  • Middle East & Africa



  • Middle East

  • Africa



Frequently Asked Questions (FAQ) :


Growing awareness regarding migraine would be the dominating factor for Migraine with Brainstem Aura Market growth.

Name segments related to a diagnosis that is a part of the Migraine with Brainstem Aura Market assessment. The segments of Migraine with Brainstem Aura Market are magnetic resonance imaging (MRI), computerized tomography (CT), and others.

Migraine with Brainstem Aura Market study includes abortive medication and preventive medication.

The study of Migraine with Brainstem Aura Market includes retail pharmacies, hospital pharmacies, and others.

The Americas would dominate global Migraine with Brainstem Aura Market study.

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Migraine with Brainstem Aura Market, by Diagnosis

6.1 Introduction

6.2 Magnetic Resonance Imaging (MRI)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3 Computerized Tomography (CT)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.4 Others

Chapter 7. Global Migraine with Brainstem Aura Market, by Treatment

7.1 Introduction

7.2 Abortive Medication

7.2.1 Non-steroidal Anti-Inflammatory Drugs (NSAIDS)

7.2.1.1 Ibuprofen

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.1.2 Others

7.2.2 Anti-Nausea Medications

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.3 Others

7.3 Preventive Medication

7.3.1 Botox Injections

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.2 Antidepressants

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.3 Others

Chapter 8. Global Migraine with Brainstem Aura Market, by Distribution Channel

8.1 Introduction

8.2 Retail Pharmacies

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3 Hospital Pharmacies

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.4 Others

Chapter 9. Global Migraine with Brainstem Aura Market, by End-User

9.1 Introduction

9.2 Hospital & Clinics

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.3 Diagnostic Centers

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.4 Others

Chapter 10. Global Migraine with Brainstem Aura Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia-Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 South Korea

10.4.6 Rest of Asia-Pacific

10.5 Middle East & Africa

10.5.1 Middle East

10.5.2 Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

Chapter 12. Company Profiles

12.1 Allergen Plc

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials Overview

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.2 Abbott Laboratories

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Merck & Co., Inc.

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Pfizer, Inc.

12.4.1 Company Overview

12.4.2 Product Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 GlaxoSmithKline plc

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 AstraZeneca

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Eisai Co., Ltd.

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financial Overview

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Endo International Plc.

12.8.1 Overview

12.8.2 Product Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Impax Laboratories

12.9.1 Overview

12.9.2 Product Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 Eli Lily and Company

12.10.1 Overview

12.10.2 Product Overview

12.10.3 Financials

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.12 Johnson & Johnson

12.11.1 Overview

12.11.2 Product Overview

12.11.3 Financials

12.11.4 Key Developments

12.11.5 SWOT Analysis

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s Viewpoint

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Predictions for the Migraine with Brainstem Aura Industry

Chapter 14. Appendix

LIST OF TABLES

Table 1 Global Migraine with Brainstem Aura Market Synopsis, 2020–2027

Table 2 Global Migraine with Brainstem Aura Market Estimates and Forecast, 2020–2027 (USD Million)

Table 3 Global Migraine with Brainstem Aura Market, by Region, 2020–2027 (USD Million)

Table 5 Global Migraine with Brainstem Aura Market, by Diagnosis, 2020–2027(USD Million)

Table 6 Global Migraine with Brainstem Aura Market, by Treatment, 2020–2027 (USD Million)

Table 6 Global Migraine with Brainstem Aura Market, by Distribution Channel, 2020–2027 (USD

Million)

Table 7 Global Migraine with Brainstem Aura Market, by End-User, 2020–2027 (USD Million)

Table 8 North America: Migraine with Brainstem Aura Market, by Diagnosis, 2020–2027 (USD

Million)

Table 9 North America: Migraine with Brainstem Aura Market, by Treatment, 2020–2027 (USD

Million)

Table 10 North America: Migraine with Brainstem Aura Market, by Distribution Channel, 2020–

2027 (USD Million)

Table 11 North America: Migraine with Brainstem Aura Market, by End-User, 2020–2027 (USD

Million)

Table 12 US: Migraine with Brainstem Aura Market, by Diagnosis, 2020–2027 (USD Million)

Table 13 US: Migraine with Brainstem Aura Market, by Treatment, 2020–2027 (USD Million)

Table 14 US: Migraine with Brainstem Aura Market, by Distribution Channel, 2020–2027 (USD

Million)

Table 15 US: Migraine with Brainstem Aura Market, by End-User, 2020–2027 (USD Million)

Table 16 Canada: Migraine with Brainstem Aura Market, by Diagnosis, 2020–2027 (USD Million)

Table 17 Canada: Migraine with Brainstem Aura Market, by Treatment, 2020–2027 (USD Million)

Table 18 Canada: Migraine with Brainstem Aura Market, by Distribution Channel, 2020–2027

(USD Million)

Table 19 Canada: Migraine with Brainstem Aura Market, by End-User, 2020–2027 (USD Million)

Table 20 South America: Migraine with Brainstem Aura Market, by Diagnosis, 2020–2027 (USD

Million)

Table 21 South America: Migraine with Brainstem Aura Market, by Treatment, 2020–2027 (USD

Million)

Table 22 South America: Migraine with Brainstem Aura Market, by Distribution Channel, 2020–

2027 (USD Million)

Table 23 South America: Migraine with Brainstem Aura Market, by End-User, 2020–2027 (USD

Million)

Table 24 Europe: Migraine with Brainstem Aura Market, by Diagnosis, 2020–2027 (USD Million)

Table 25 Europe: Migraine with Brainstem Aura Market, by Treatment, 2020–2027 (USD Million)

Table 26 Europe: Migraine with Brainstem Aura Market, by Distribution Channel, 2020–2027 (USD

Million)

Table 27 Western Europe: Migraine with Brainstem Aura Market, by Diagnosis, 2020–2027 (USD

Million)

Table 28 Western Europe: Migraine with Brainstem Aura Market, by Treatment, 2020–2027 (USD

Million)

Table 29 Western Europe: Migraine with Brainstem Aura Market, by Distribution Channel, 2020–

2027 (USD Million)

Table 30 Western Europe: Migraine with Brainstem Aura Market, by End-User, 2020–2027

(USD Million)

Table 31 Eastern Europe: Migraine with Brainstem Aura Market, by Diagnosis, 2020–2027 (USD

Million)

Table 32 Eastern Europe: Migraine with Brainstem Aura Market, by Treatment, 2020–2027 (USD

Million)

Table 33 Eastern Europe: Migraine with Brainstem Aura Market, by Distribution Channel, 2020–

2027 (USD Million)

Table 34 Eastern Europe: Migraine with Brainstem Aura Market, by End-User, 2020–2027

(USD Million)

Table 35 Asia-Pacific: Migraine with Brainstem Aura Market, by Diagnosis, 2020–2027 (USD

Million)

Table 36 Asia-Pacific: Migraine with Brainstem Aura Market, by Treatment, 2020–2027 (USD

Million)

Table 37 Asia-Pacific: Migraine with Brainstem Aura Market, by Distribution Channel, 2020–2027

(USD Million)

Table 38 Asia-Pacific: Migraine with Brainstem Aura Market, by End-User, 2020–2027 (USD

Million)

Table 39 Middle East & Africa: Migraine with Brainstem Aura Market, by Diagnosis, 2020–2027

(USD Million)

Table 40 Middle East & Africa: Migraine with Brainstem Aura Market, by Treatment, 2020–2027

(USD Million)

Table 41 Middle East & Africa: Migraine with Brainstem Aura Market, by Distribution Channel,

2020–2027 (USD Million)

Table 42 Middle East & Africa: Migraine with Brainstem Aura Market, by End-User, 2020–2027

(USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for the Global Migraine with Brainstem Aura Market

Figure 3 Segmentation Market Dynamics for Global Migraine with Brainstem Aura Market

Figure 4 Global Migraine with Brainstem Aura Market Share, by Type, 2020

Figure 5 Global Migraine with Brainstem Aura Market Share, by Diagnosis, 2020

Figure 6 Global Migraine with Brainstem Aura Market Share, by Treatment, 2020

Figure 7 Global Migraine with Brainstem Aura Market Share, by Distribution Channel, 2020

Figure 8 Global Migraine with Brainstem Aura Market Share, by End-User, 2020

Figure 9 Global Migraine with Brainstem Aura Market Share, by Region, 2020

Figure 10 North America: Migraine with Brainstem Aura Market Share, by Country, 2020

Figure 11 Europe: Migraine with Brainstem Aura Market Share, by Country, 2020

Figure 12 Asia-Pacific: Migraine with Brainstem Aura Market Share, by Country, 2020

Figure 13 Middle East & Africa: Migraine with Brainstem Aura Market Share, by Country, 2020

Figure 14 Global Migraine with Brainstem Aura Market: Company Share Analysis, 2020 (%)

Figure 15 Allergen Plc: Key Financials

Figure 16 Allergen Plc: Segmental Revenue

Figure 17 Allergen Plc: Geographical Revenue

Figure 18 Abbott Laboratories: Key Financials

Figure 19 Abbott Laboratories: Segmental Revenue

Figure 20 Abbott Laboratories: Geographical Revenue

Figure 21 Merck & Co., Inc.: Key Financials

Figure 22 Merck & Co., Inc.: Segmental Revenue

Figure 23 Merck & Co., Inc.: Geographical Revenue

Figure 24 Pfizer, Inc.: Key Financials

Figure 25 Pfizer, Inc: Segmental Revenue

Figure 26 Pfizer, Inc: Geographical Revenue

Figure 27 GlaxoSmithKline plc: Key Financials

Figure 28 GlaxoSmithKline plc: Segmental Revenue

Figure 29 GlaxoSmithKline Plc. Geographical Revenue

Figure 30 AstraZeneca: Key Financials

Figure 31 AstraZeneca: Segmental Revenue

Figure 32 AstraZeneca: Geographical Revenue

Figure 33 Eisai Co., Ltd.: Key Financials

Figure 34 Eisai Co., Ltd.: Segmental Revenue

Figure 35 Eisai Co., Ltd.: Geographical Revenue

Figure 36 Endo International Plc.: Key Financials

Figure 37 Endo International Plc.: Segmental Revenue

Figure 38 Endo International Plc.: Geographical Revenue

Figure 39 Impax Laboratories: Key Financials

Figure 40 Impax Laboratories: Segmental Revenue

Figure 41 Impax Laboratories: Geographical Revenue

Figure 42 Eli Lily and Company: Key Financials

Figure 43 Eli Lily and Company: Segmental Revenue

Figure 44 Eli Lily and Company: Geographical Revenue

Figure 45 Johnson & Johnson: Key Financials

Figure 46 Johnson & Johnson: Segmental Revenue

Figure 47 Johnson & Johnson: Geographical Revenue